专利号:US-9265748-B2 优先权日:2011-08-11 标题 :Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use 发明人:RAILLARD STEPHEN P; MANTHATI SURESH K; JOSHI SUDHIR 权利人:XENOPORT INC 摘要:Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxyl)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxyl)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.
专利号:WO-2024097977-A1 优先权日:2022-11-04 标题:Silk nanoparticle synthesis: tuning size, dispersity, and surface chemistry for drug delivery 发明人:SHAIDANI SAWNAZ; FALCUCCI THOMAS; FOSTER OLIVIA; SAHOO JUGAL KISHORE; HASTURK ONUR; KAPLAN DAVID L; JACOBUS CHARLOTTE S 权利人:TUFTS COLLEGE 摘要:Methods disclosed herein relate to generating silk nanoparticles with a low polydispersity index (PDI). Methods include adding a silk solution dropwise into a volatile solvent that is miscible with water, thereby forming a precipitate-bearing solution and applying shear forces to the precipitate-bearing solution for a length of time sufficient to achieve evaporation of at least 95% of the volatile solvent, thereby producing a population of silk fibroin nanoparticles in water having a polydispersity index (PDI) of 0.35 or less, including but not limited to, a PDI of 0.330 or less, 0.325 or less, 0.315 or less, 0.310 or less, 0.30 or less, 0.275 or less, 0.250 or less, 0.225 or less, or 0.200 or less. Parameters related to silk fibroin molecular weight, silk fibroin concentration, shear force application, and temperature may all be modified to achieve silk nanoparticles of a particular size exhibiting particular PDIs.
专利号:US-2024091199-A1 优先权日:2017-06-30 标 题:Deuterated Domperidone Compositions, Methods, and Preparation 发明人:PEARCE CATHERINE; ISAACSOHN JON; PATEL PIYUSH 权利人:CINDOME PHARMA INC 摘要:Deuterated domperidone compositions, methods of synthesis, methods of use, and dosing formulations providing beneficial safety and other effects.
专利号:US-2015313865-A1 优先权日:2011-08-11 标 题:Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use
专利号:US-2014066501-A1 优先权日:2011-08-11 标 题:Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use
专利号:US-8580850-B2 优先权日:2011-08-11 标题 :Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
1: Bryson E, Hartman R, Arnold J, Gorman G, Sweitzer S, Asbill S. Skin Permeation and Antinociception of Compounded Topical Cyclobenzaprine Hydrochloride Formulations. Int J Pharm Compd. 2015 Mar-Apr;19(2):161-6. 3: Bulbena-Cabre A, Dunn NR, Swift RG. Cyclobenzaprine-Induced Hallucinosis. Prim Care Companion CNS Disord. 2015 Jun 25;17(3). doi: 10.4088/PCC.14l01773. eCollection 2015. 4: Friedman BW, Dym AA, Davitt M, Holden L, Solorzano C, Esses D, Bijur PE, Gallagher EJ. Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial. JAMA. 2015 Oct 20;314(15):1572-80. doi: 10.1001/jama.2015.13043. doi: 10.1089/ther.2015.0006. Epub 2015 Jul 8. doi: 10.3109/15563650.2015.1040157. Epub 2015 May 8. Available from http://www.ncbi.nlm.nih.gov/books/NBK279656/ doi: 10.1097/DER.0000000000000099. doi: 10.1007/s10162-014-0500-x. Epub 2014 Dec 20.
合成参考文献
摘要:Psychotropic Drugs and Related Compounds, 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972, -(87), 1972 摘要:Journal of Clinical Psychiatry., 54(39), 1993 摘要:Archives Internationales de Pharmacodynamie et de Therapie., 144(481), 1963 [] 参考文献:10.1007/s11894-012-0299-8 摘要:Stine JG, Sateesh P, Lewis JH. Drug-induced liver injury in the elderly. Curr Gastroenterol Rep. 2013 Jan;15(1):299. doi: 10.1007/s11894-012-0299-8.